It was said, no new evidence was revealed in the trial that would go against the Judge's ruling for injunction AND her dismissal of their appeal on that ruling for injunction. Twice, the Judge said no, you broke the contract agreement. So we have two things to consider, the Judge's earlier ruling and the jury's decision.
The jury should never be the one to determine complicated contract law, that is where the Judge should have told the jury that the contract was broken by Diablo, the only question for the jury was, did they use Netlist chips. The judge already deemed that they were Netlist chips, but were they used, and the Judge told them, post trial, "You used them, you used them... I have to deal with that in the context of this verdict"
EV3 is NVRAM, works in DDR3 and DDR4 based hardware, easy to integrate.
High speed an endurance of DRAM with the non-volatility of MLC NAND flash gives EV3 a performance advantage over SSDs.
CEO has been doing fine, getting high rates of billing collections, they've gotten a lot of coverage for their offerings. Revenues and tests continue to increase nicely, as well as customers. The one major blemish was the litigation that they couldn't control.
So look at it this way, assume $4.2M CapEx,
$2.75M revenue Q3, loss ($1.45M),
$3.1M rev Q4, loss ($1.1M)
$3.5M rev Q1 '16 loss ($0.7M)
$3.9M rev Q2 '16 loss ($0.3M)
That is $3.65M use in cash, and they have $7M now, they could sail through to the end of Q2 in 2016 before a need to think about raising cash, and it won't be much need. 2M shares at $2.25 would be plenty. Conservative look at things.
They will probably push out 2 more quarters of growth to show the world they are legit, they would likely raise another $5-$10M cash sometime early next year. They should have enough cash for 4Q now.
People are probably shorting, routine response to these PRs, based on Celsion's rep for having a failed PIII, even though China might want ThermoDox approved.
$2.55M revenue, all we need is $1.6M more to break even (roughly). With more product offerings and larger sales team, they should see over $3M this year, probably Q4 as I posted earlier. With the low no. of outstanding shares, if they bring home $5M revenue in a quarter, that is getting close to 0.10 EPS That is why you invest here, it won't be long before they are seeing $5M revenue per Q (IMO) and the price appreciation will be impressive due to low # shares.
They presented at Cantor Fitzgerald in July and they posted their updated corporate presentation under that Event at their website. In that presentation, they discussed upcoming 2nd half milestones and partnering for TheraSilence was a bullet point... Tardugno also said they partnered costs 50-50 with known name Pharma for the recently conducted early phase trial, in the prior earnings call, also available on the net, transcript. That should be, Egen was partnered for early phase studies and Celsion expects to continue partnering.
Add up all the expenses of litigation, time = money, they spent over $2M defending themselves, and they invested time in the defense. We'd be much better off if there had been no litigation. That is out of their control.
There were like 10+ modern gasses that were sent to the US Navy for testing, MG1 was one of the three that passed their tests, MG2 is better than MG1. If all these companies could churn out modern, safer gasses then why did so many fail the US Navy tests?
I'd look for $80M revenue this year as a fair goal, 0.20EPS, some solid cash generation from operations. Should be 2x sales at least, considering virgin R-22 supplies ending and the high potential for the same thing to happen to HFCs now that India is on board for amending the Montreal protocol.
Another reason the FDA could approve RCW early is that Doxorubicin is a known entity, systemic use, used in Doxil, decades of use. "The recommended dose of Doxorubicin hydrochloride when used as a single agent is 60 to 75 mg/m2 intravenously every 21 days." ThermoDox just refines the delivery, making it safer.
"OPTIMA study is now enrolling patients at over 40 sites in 12 of 13 targeted countries and with the support of regulatory and the medical community, the OPTIMA study is now nearly 10% enrolled" from last earnings call